Amylin Pharmaceuticals Inc - Statement of Changes in Beneficial Ownership (4)
March 20 2008 - 2:35PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
January 31, 2008
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
BRADBURY DANIEL
|
2. Issuer Name
and
Ticker or Trading Symbol
AMYLIN PHARMACEUTICALS INC
[
AMLN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
President & Chief Executive Of
|
(Last)
(First)
(Middle)
9360 TOWNE CENTRE DR
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/4/2008
|
(Street)
SAN DIEGO, CA 92121
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
3/4/2008
|
|
G
(1)
|
V
|
40
|
D
|
$0
|
46369
(2)
|
I
|
by Trust
(3)
|
Common Stock
|
3/19/2008
|
|
G
|
V
|
1790
|
D
|
$0
|
44579
|
I
|
by Trust
(3)
|
Common Stock
|
3/19/2008
|
|
G
|
V
|
1790
|
A
|
$0
|
6263
|
I
|
by Trust-1
(4)
|
Common Stock
|
|
|
|
|
|
|
|
12612
|
D
|
|
Common Stock
|
|
|
|
|
|
|
|
905
|
I
|
by ESOP
(5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(
1)
|
This represents a gift by the reporting person to a 501(c)3 corporation.
|
(
2)
|
Includes 502 shares acquired on February 29,2008 under the company's employee stock purchase plan.
|
(
3)
|
Shares held by the Bradbury Family Trust #3.
|
(
4)
|
Shares held by the Bradbury Gift Trust, of which the reporting person's minor children are beneficiaries.
|
(
5)
|
Reflects ESOP allocations that have occurred since the date of the reporting person's last ownership report. These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
BRADBURY DANIEL
9360 TOWNE CENTRE DR
SAN DIEGO, CA 92121
|
X
|
|
President & Chief Executive Of
|
|
Signatures
|
By: /s/James R. Oehler, Attorney-in-Fact For: Daniel M. Bradbury
|
|
3/20/2008
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Sep 2023 to Sep 2024